COVID-19 drug practices risk antimicrobial resistance evolution
Research output: Contribution to journal › Comment/debate › Research › peer-review
Standard
COVID-19 drug practices risk antimicrobial resistance evolution. / MetaSUB Consortium.
In: The Lancet Microbe, Vol. 2, No. 4, 2021, p. e135-e136.Research output: Contribution to journal › Comment/debate › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - COVID-19 drug practices risk antimicrobial resistance evolution
AU - Afshinnekoo, Ebrahim
AU - Bhattacharya, Chandrima
AU - Burguete-García, Ana
AU - Castro-Nallar, Eduardo
AU - Deng, Youping
AU - Desnues, Christelle
AU - Dias-Neto, Emmanuel
AU - Elhaik, Eran
AU - Iraola, Gregorio
AU - Jang, Soojin
AU - Łabaj, Paweł P.
AU - Mason, Christopher E.
AU - Nagarajan, Niranjan
AU - Poulsen, Michael
AU - Prithiviraj, Bharath
AU - Siam, Rania
AU - Shi, Tieliu
AU - Suzuki, Haruo
AU - Werner, Johannes
AU - Zambrano, Maria Mercedes
AU - Bhattacharyya, Malay
AU - MetaSUB Consortium
PY - 2021
Y1 - 2021
U2 - 10.1016/S2666-5247(21)00039-2
DO - 10.1016/S2666-5247(21)00039-2
M3 - Comment/debate
AN - SCOPUS:85103372304
VL - 2
SP - e135-e136
JO - The Lancet Microbe
JF - The Lancet Microbe
SN - 2666-5247
IS - 4
ER -
ID: 261376656